Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Cardiac Marker Testing Market analysis
Part of: Cardiac Marker Testing Market (Global)

The UK Cardiac Marker Testing Market was valued at $34.4 Million in 2026 and projected to reach to $65.6 Million by 2031, representing a compound annual growth rate of 13.8%. The UK cardiac marker testing market is positioned for sustained expansion through 2031, driven by an aging population with elevated cardiovascular risk and growing clinical awareness of early detection benefits.

UK Cardiac Marker Testing Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Cardiac Marker Testing Market Trends and Insights

  • The UK market is expanding at a compound annual growth rate of 13.8%, significantly outpacing global trends, driven by increasing prevalence of cardiovascular diseases and rising demand for rapid diagnostic solutions.
  • The UK's advanced healthcare infrastructure and emphasis on early disease detection are key catalysts for this expansion. In the UK, cardiac marker testing adoption is accelerating across hospitals, diagnostic laboratories, and point-of-care settings.
  • The UK's aging population and growing awareness of cardiac health are fueling demand for troponin, BNP, and other biomarker assays.
  • Between 2026 and 2031, the UK market is expected to nearly double, reflecting strong investment in cardiac diagnostics and the integration of high-sensitivity testing platforms throughout the UK healthcare system..

Key Market Statistics

  • CAGR (2026-2031) 13.8% CAGR
  • Market Size, 2026 ~USD 34.4 Million
  • Forecast, 2031 ~USD 65.6 Million
  • Country UK

UK Cardiac Marker Testing Market Overview

Exceptional Growth Trajectory :

The UK cardiac marker testing market is expanding at 13.8% CAGR, nearly 35% faster than the global average of 10.3%, reflecting strong domestic demand and healthcare investment.

Market Valuation Surge :

Market size is projected to nearly double from $34.4 million in 2026 to $65.6 million by 2031, demonstrating significant revenue opportunities for stakeholders in the UK healthcare sector.

Cardiovascular Disease Prevalence :

Rising incidence of cardiovascular diseases across the UK population is driving increased adoption of cardiac marker testing as a critical diagnostic tool in clinical practice.

Advanced Healthcare Infrastructure :

The UK's sophisticated healthcare system, including the NHS and private sector, supports rapid adoption of innovative diagnostic technologies and testing methodologies.

UK Cardiac Marker Testing Market Dynamics

  • NHS initiatives promoting preventive cardiology and the integration of high-sensitivity troponin assays into standard protocols are accelerating market penetration.
  • Private healthcare providers are also investing in advanced testing capabilities to meet patient demand for rapid, accurate diagnostics. Technological advancements in point-of-care testing and digital health integration will further enhance market growth.
  • Regulatory support from UK health authorities and increasing reimbursement coverage for cardiac biomarker testing create a favorable environment for market expansion.
  • Strategic partnerships between diagnostic manufacturers and healthcare institutions will strengthen distribution networks and drive adoption across primary and secondary care settings..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
    Top Companies

      Medical Devices

      Top Technologies
        Top Companies

          Key Takeaways

          • The UK cardiac marker testing market will nearly double from $34.4M (2026) to $65.6M (2031), driven by a 13.8% CAGR.
          • The UK's advanced healthcare infrastructure and aging population are primary growth drivers for cardiac diagnostic adoption.
          • High-sensitivity troponin assays and BNP testing are gaining traction across UK hospitals and diagnostic centers.
          • The UK market growth rate of 13.8% significantly exceeds the global average, positioning the UK as a high-growth region.

          Cardiac Marker Testing Market Report Scope

          Report Metric Details
          Base Year 2026
          Fastest Growing Segment OTHER CARDIAC BIOMARKERS (Biomarker Type)
          Forecast Period 2026–2031
          Growth Rate CAGR of 10.3% from 2026 to 2031
          Largest Segment SINGLEPLEX ASSAY (Assay Format)
          Market Size Base Year (Billions) ~USD 5.55 (2026)
          Revenue Forecast (Billions) ~USD 9.06 (2031)
          Segments Covered Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User

          UK Cardiac Marker Testing Market Report Segmentation

          8 segment dimensions are covered across the global market.

          By Product

          • Instruments
          • Reagents & Kits

          By Technology

          • Clinical Chemistry
          • Immunoassay
          • Immunoassays

          By Type

          • Chemiluminescence
          • Contract Testing Laboratories
          • Elisa
          • Hospital Laboratories
          • Immunofluorescence
          • Lateral Flow Immunoassay
          • Reference Laboratories

          By Indication

          • Acute Coronary Syndrome
          • Atherosclerosis
          • Congestive Heart Failure
          • Ischemia
          • Myocardial Infarction

          By Biomarker Type

          • Brain Natriuretic Peptide
          • Creatinine Kinase-Mb
          • High-Sensitivity C-Reactive Protein
          • Homocysteine
          • Myoglobin
          • Other Cardiac Biomarkers
          • Troponin I & T

          By Point Of Testing

          • Lab Tests
          • Poc Tests

          By Assay Format

          • Multiplex Assay
          • Multiplex Assays
          • Singleplex Assay
          • Singleplex Assays

          By End User

          • Academic Institutes
          • Laboratory Testing Facilities
          • Point-Of-Care Testing

          UK: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031

          Segment20242025202620272028202920302031CAGR (%)
          ACADEMIC INSTITUTES33.134.538.643.348.855.262.671.113
          LABORATORY TESTING FACILITIES158.3163.3180.7200.4223.1249.3279.4313.411.6
          POINT-OF-CARE TESTING74.178.188.3100113.8130148.9170.914.1
          TOTAL265.5275.9307.6343.8385.7434.5490.9555.412.5

          Target Audience

          • Diagnostic Equipment Manufacturers : Need UK market data to assess demand for cardiac testing devices, identify distribution partnerships with NHS trusts, and develop region-specific product strategies.
          • In Vitro Diagnostics (IVD) Companies : Require detailed market sizing and growth projections to guide R&D investments, clinical trial planning, and regulatory submissions for UK market approval.
          • Healthcare Investment Firms : Seek comprehensive market analysis to evaluate acquisition targets, assess portfolio company growth potential, and identify emerging opportunities in UK cardiac diagnostics.
          • NHS Procurement & Hospital Administrators : Need market intelligence on testing technologies, cost-effectiveness data, and supplier landscapes to optimize procurement decisions and improve cardiac care delivery.
          • Healthcare Consultants & Strategy Advisors : Require UK-specific market insights to advise clients on market positioning, competitive strategies, and growth opportunities in the cardiac testing sector.

          Key Companies in the UK Cardiac Marker Testing Market

          CompanyHQOwnershipStrongest segments
          ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
          DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software),
          SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
          THERMO FISHER SCIENTIFICUnited StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
          BIO-RAD LABORATORIESUnited StatesPublic CompanyLife Science,Clinical Diagnostics,
          BIOMéRIEUX SAFrancePublic CompanyClinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA),
          BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
          DIASORIN SPAItalyPublic CompanyImmunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory,
          REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software,
          TOSOH CORPORATIONJapanPublic CompanyBasic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins),
          QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care,
          GUANGZHOU WONDFO BIOTECH CO., LTD.ChinaPublic CompanyRapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform,

          ABBOTT LABORATORIES

          Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.

          DANAHER CORPORATION

          Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.

          SIEMENS HEALTHINEERS AG

          Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.

          THERMO FISHER SCIENTIFIC

          Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

          BIO-RAD LABORATORIES

          Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.

          BIOMéRIEUX SA

          bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.

          BECTON, DICKINSON AND COMPANY

          Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.

          DIASORIN SPA

          DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.

          REVVITY

          Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

          TOSOH CORPORATION

          Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.

          QUIDEL CORPORATION

          Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.

          GUANGZHOU WONDFO BIOTECH CO., LTD.

          Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.

          Reasons to Buy this Report

          • Market Size & Growth Validation : Confirm the UK market's exceptional 13.8% CAGR and validate investment decisions with precise valuation data spanning 2026-2031, enabling accurate financial forecasting.
          • Competitive Landscape Intelligence : Understand UK-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies tailored to the British healthcare ecosystem.
          • NHS & Healthcare Policy Insights : Access detailed analysis of UK healthcare regulations, NHS procurement trends, and reimbursement pathways critical for aligning products and services with national health priorities.
          • Regional Demand Drivers : Leverage UK-specific epidemiological data on cardiovascular disease prevalence and demographic trends to identify high-opportunity segments and geographic hotspots for expansion.
          • Strategic Planning & Risk Mitigation : Make informed decisions on resource allocation, product development, and market entry timing with comprehensive UK market forecasts and scenario analysis through 2031.

          Frequently asked questions

          What is the current size of the UK cardiac marker testing market?

          The UK cardiac marker testing market is valued at $34.4 million in 2026 and is projected to grow to $65.6 million by 2031.

          What is the growth rate of the UK cardiac marker testing market?

          The UK market is growing at a compound annual growth rate (CAGR) of 13.8% from 2026 to 2031.

          What factors are driving growth in the UK cardiac marker testing market?

          Key drivers include the UK's aging population, rising cardiovascular disease prevalence, advanced healthcare infrastructure, and increased adoption of high-sensitivity diagnostic platforms.

          Which cardiac markers are most commonly tested in the UK?

          The UK market shows strong demand for high-sensitivity troponin assays, B-type natriuretic peptide (BNP), and other cardiac biomarkers used in acute coronary syndrome and heart failure diagnosis.

          How does the UK market compare to global cardiac marker testing growth?

          The UK's 13.8% CAGR significantly outpaces the global average of 10.3%, making the UK one of the fastest-growing regions for cardiac marker testing.

          RESEARCH METHODOLOGY

          The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.

          Secondary Research

          In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

          Primary Research

          In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

          BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS

          Cardiac Marker Testing Market Size, and Share

          Note 1: Others include sales managers, marketing managers, and product managers.
          Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

          COMPANY NAME

          DESIGNATION

          Abbott Laboratories (US)

          Sales Manager

          F. Hoffmann-La Roche AG (Switzerland)

          Product Manager

          To know about the assumptions considered for the study, download the pdf brochure

          Market Size Estimation

          Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:

          • The key players in the industry have been identified through extensive secondary research
          • The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
          • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

          The research methodology used to estimate the market size includes the following:

          Cardiac Marker Testing Market Top Down and Bottom Up Approach

          Data Triangulation

          After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

          Market Definition

          Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).

          Key Stakeholders

          • Product Manufacturers, Distributors, and Suppliers
          • Diagnostic Laboratories and Point-of-care Testing Centers
          • Research Laboratories and CROs
          • Ambulatory Testing Centers
          • Contract Testing Laboratories
          • Academic Universities and Medical Research Centers
          • Research & Development (R&D) Centers

          Report Objectives

          • To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
          • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
          • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
          • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
          • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
          • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
          • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
          • To study the impact of AI on the market, along with the macroeconomic outlook for each region

          Available customizations:

          MarketsandMarkets offers the following customizations for this market report.

          Country Information

          • Additional country-level analysis of the cardiac marker testing market

          Company profiles

          • Additional five company profiles of players operating in the cardiac marker testing market.

          Product Analysis

          • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market

           

          Get the Full Cardiac Marker Testing Market Report

          Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.

          Download Sample Pages Buy Report

          METHODOLOGY

          Need a Tailored Report?

          Customize this report to your needs

          Get 10% FREE Customization

          Customize This Report
          Fact checked
          Cite this Research
          DMCA.com Protection Status